Back to search resultsSummaryRMgm-1252
|
||||||||||
*RMgm-1252| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene disruption, Introduction of a transgene |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 25960542 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei ANKA |
| Name parent line/clone | Not applicable |
| Other information parent line | |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | Jaijyan DK, Singh H, Singh AP |
| Name Group/Department | Infectious Diseases Laboratory |
| Name Institute | National Institute of Immunology, Aruna Asaf Ali Marg |
| City | New Delhi |
| Country | India |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-1252 |
| Principal name | PbĪSLTRiP::hDHFR&GFP |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | Not different from wild type |
| Gametocyte/Gamete | Not different from wild type |
| Fertilization and ookinete | Not tested |
| Oocyst | Not different from wild type |
| Sporozoite | Not different from wild type |
| Liver stage | Reduction of the number of liver stages in vivo (21-fold fewer) and in vitro. One day delay in prepatent period in mice infected with mutant sporozoites. Evidence is presented for a reduced size of liver stages. |
| Additional remarks phenotype | Mutant/mutation Multiple sequence alignments shows that a segment of SLTRiP is conserved in Plasmodium species and contains a large number of position-constrained conserved tryptophan residues SLTRiP also contains a few cysteines (3 in P. berghei), but these are not conserved among other species. In GeneDB (www.genedb.org) the PBANKA_070100 gene has been annotated as pseudogene (containing a frameshift). |
Disrupted: Mutant parasite with a disrupted gene| top of page | |||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PBANKA_0701000 | ||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_0830500 | ||||||||||||||||||||||||
| Gene product | sporozoite and liver stage tryptophan-rich protein, putative | tryptophan-rich antigen | ||||||||||||||||||||||||
| Gene product: Alternative name | TryThrA; SLTRiP | ||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||||||||
| Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||||||||
| Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
| Additional remarks partial/complete disruption | |||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||
| Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||
| Additional remarks genetic modification | |||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||
|
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||
Transgene: Mutant parasite expressing a transgene| top of page | |||||||||||||||||||
| Type and details of transgene | |||||||||||||||||||
| Is the transgene Plasmodium derived | Transgene: not Plasmodium | ||||||||||||||||||
| Transgene name | GFP | ||||||||||||||||||
| top of page | |||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||
| Type of plasmid/construct | (Linear) plasmid double cross-over | ||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||
| Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||
| Promoter of the selectable marker | pbdhfr | ||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||
| Additional remarks genetic modification | |||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||
| top of page | |||||||||||||||||||
| Other details transgene | |||||||||||||||||||
| top of page | |||||||||||||||||||
| Promoter | |||||||||||||||||||
| Gene Model of Parasite | Not available | ||||||||||||||||||
| Gene Model P. falciparum ortholog | Not available | ||||||||||||||||||
| Gene product | Not available | ||||||||||||||||||
| Gene product: Alternative name | |||||||||||||||||||
| |||||||||||||||||||
| top of page | |||||||||||||||||||
| 3'-UTR | |||||||||||||||||||
| Gene Model of Parasite | Not available | ||||||||||||||||||
| Gene product | Not available | ||||||||||||||||||
| Gene product: Alternative name | |||||||||||||||||||
| |||||||||||||||||||
| Insertion/Replacement locus | |||||||||||||||||||
| Replacement / Insertion | Replacement locus | ||||||||||||||||||
| Gene Model of Parasite | PBANKA_0701000 | ||||||||||||||||||
| Gene product | sporozoite and liver stage tryptophan-rich protein, putative | ||||||||||||||||||
| Gene product: Alternative name | TryThrA; SLTRiP | ||||||||||||||||||
| |||||||||||||||||||
| top of page | |||||||||||||||||||